CLINICAL_TRIALS
ClinicalTrials.gov record update
Safety and Efficacy of Anti-CD123 Chimeric Antigen Receptor-Modified Autologous T Cells (CART123) in Patients With Relapsed/Refractory CD123+ Hematologic Malignancies: A Dose Escalation, Open-Label, Phase I Study
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT06765876
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:28:39.218652+00:00
- Published At
- 2026-01-12T00:00:00+00:00
- Record Updated At
- 2026-01-12
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Leukemia, Myeloid, Acute(AML)", "Precursor Cell Lymphoblastic Leukemia-Lymphoma", "Myelodysplastic Syndromes (MDS)", "Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-01-12"- protocolSection.identificationModule.nctId
"NCT06765876"- protocolSection.identificationModule.officialTitle
"Safety and Efficacy of Anti-CD123 Chimeric Antigen Receptor-Modified Autologous T Cells (CART123) in Patients With Relapsed/Refractory CD123+ Hematologic Malignancies: A Dose Escalation, Open-Label, Phase I Study"- protocolSection.statusModule.overallStatus
"RECRUITING"- protocolSection.designModule.phases
["EARLY_PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.